Host cells and methods of use

Patent metadata

Field	Value
Publication number	US-9926570-B2
Application number	US-201414772436-A
Country	US
Kind code	B2
Filing date	Mar 6, 2014
Priority date	Mar 6, 2013
Publication date	Mar 27, 2018
Grant date	Mar 27, 2018

Abstract

The present invention relates to genetically modified host cells, in particular yeast cells, comprising at least one isolated polynucleotide encoding a Killer Expression protease (Kex2p) or a fragment and/or variant thereof which has at least one Kex2p functional activity and at least one isolated polynucleotide encoding a Protein Disulfide-Isomerase (Pdi1) or a fragment and/or variant thereof which has at least one Pdi functional activity. Also provided herein are genetically modified host cells comprising at least one isolated polynucleotide encoding a Killer Expression protease (Kex2p) or a fragment and/or variant thereof which has at least one Kex2p functional activity, at least one isolated polynucleotide encoding a Protein Disulfide-Isomerase (Pdi1) or a fragment and/or variant thereof which has at least one Pdi1 functional activity and at least one isolated polynucleotide encoding a Endoplasmic Reticulum Oxidoreductin (Ero1) or a fragment and/or variant thereof which has at least one Ero1 functional activity.

First claim

We claim:

1. A host cell comprising at least one heterologous nucleic acid sequence encoding a Killer Expression protease (Kex2p) having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 4, and at least one heterologous nucleic acid sequence encoding a Protein Disulfide-Isomerase (Pdi1) having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 6, and at least one heterologous nucleic acid sequence encoding an Endoplasmic Reticulum Oxidoreductin (Ero1) having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 8.

2. The host cell of claim 1 , wherein said host cell expresses or overexpresses at least one gene product of said at least one heterologous nucleic acid sequence encoding a protein selected from: a Kex2p protein having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 4, a Pdi1 protein having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 6 and a Ero1 protein having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 8 when said host cell is grown in culture.

3. The host cell of claim 1 wherein said host cell is a yeast cell.

4. The host cell of claim 3 , wherein the genera of said yeast cell is selected from the group consisting of: Saccharomyces, Kluyveromyces, Candida, Pichia, Schizosaccharomyces, Hansenula, Kloeckera, Schwanniomyces , and Yarrowia.

5. The host cell of claim 4 wherein said host cell is Saccharomyces cerevisiae.

6. The host cell of claim 1 , wherein said host cell further comprises at least one of the following genetic modifications: pep4 protease knockout, lower ubc4 and/or ubc5 activity compared with wild type host cell, yps1 knockout, hsp150 knockout, and pmt1 knockout.

7. The host cell of claim 1 comprising at least one nucleic acid encoding a recombinant polypeptide.

8. The host cell of claim 7 wherein said recombinant polypeptide has at least one disulfide bond.

9. The host cell of claim 7 wherein said recombinant polypeptide is an albumin fusion protein.

10. The host cell of claim 7 wherein said recombinant polypeptide has a polypeptide having at least 95% sequence identity to the amino acid sequence set forth in SEQ ID NO:1.

11. The host cell of claim 7 wherein the recombinant polypeptide comprises an amino acid sequence set forth in SEQ ID NO:1.

12. The host cell of claim 1 wherein said Kex2p is encoded by the nucleic acid sequence set forth in SEQ ID NO:3.

13. The host cell of claim 1 wherein said Pdi1 is encoded by the nucleic acid sequence set forth in SEQ ID NO:5.

14. The host cell of claim 1 wherein said Ero1 is encoded by the nucleic acid sequence set forth in SEQ ID NO:7.

15. The host cell of claim 1 further comprising at least one nucleic acid encoding a recombinant polypeptide wherein said host cell increases the titre yield of said recombinant polypeptide when grown in culture compared with a host cell of the same species and genetic modifications but which does not comprise at least one heterologous nucleic acid sequence encoding a Killer Expression protease (Kex2p) having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 4, at least one heterologous nucleic acid sequence encoding a Protein Disulfide-Isomerase (Pdi1) having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 6, and at least one heterologous nucleic acid sequence encoding a Endoplasmic Reticulum Oxidoreductin (Ero1) having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 8.

16. A method of producing a recombinant polypeptide comprising culturing a host cell of claim 7 and recovering said recombinant polypeptide from culture medium.

17. A host cell which overexpresses a Killer Expression protease (Kex2p) having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:4, a Protein Disulfide-Isomerase (Pdi1) having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 6, and a Endoplasmic Reticulum Oxidoreductin (Ero11 having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 8 when said host cell is grown in culture compared to wild type host cell wherein said wild type host cell is the same species and grown in the same culture conditions.

Assignees

• Glaxosmithkline Llc

Inventors

• Jin Yonghwan
• Zhu Yuan

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P3/08

  for glucose homeostasis (pancreatic hormones A61P5/48) · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title